MSC Therapy for Burn Wounds and Chronic Skin Regeneration: 2026 Breakthroughs in Exosome-Based Healing

New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.

Lire la suite...

Stem Cells and Alzheimer’s Disease: A Patient’s Guide to What 2026 Research Shows

2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.

Lire la suite...

The First FDA-Approved Stem Cell Therapy for Type 1 Diabetes: What Zimislecel Means for Patients in 2026

Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.

Lire la suite...

MSC Therapy for Degenerative Disc Disease: A 2026 Meta-Analysis of Randomized Trials and the Cell-Free Exosome Frontier

A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.

Lire la suite...

MSC Therapy for Pulmonary Arterial Hypertension: Mechanisms, Mitochondrial Repair.

Pulmonary arterial hypertension kills half its patients within five years. 2026 research shows mesenchymal stem cells — especially HO-1-modified and mitochondria-primed MSCs — are reversing the vascular remodeling at the disease’s core. Here’s the science behind the breakthrough.

Lire la suite...
Top